Samik Pharm.
Financials
Valuation Metrics
Samik Pharm.'s Market Cap is ₩1006B. Ranked #1281 of 2,421 in KR market (top 53%), #700 of 1,640 on KOSDAQ (top 43%), #140 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 61%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 100.58B KRW | KR#1,281/2,421 Sec#140/231 |
| Revenue | 60.02B KRW | KR#1,699/2,421 Sec#114/231 |
| Net Income | -754.9M KRW | KR—/2,421 Sec—/231 |
| Total Assets | 85.22B KRW | KR#1,899/2,421 Sec#153/231 |
| Net Assets | 68.98B KRW | KR#1,691/2,421 Sec#143/231 |
| Value | ||
| P/B | 1.46x | KR#1,756/2,421 Sec#123/231 |
| P/S | 1.68x | KR#1,701/2,421 Sec#98/231 |
| EV/EBITDA | 29.96x | KR#1,198/2,421 Sec#75/231 |
| FCF Yield | -1.34% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -1.09% | KR#1,629/2,421 Sec#112/231 |
| ROA | -0.89% | KR#1,665/2,421 Sec#115/231 |
| Op. Margin | 5.45% | KR#903/2,421 Sec#66/231 |
| Financial Health | ||
| Debt Ratio | 23.54% | KR#455/2,421 Sec#54/231 |
| Total Debt | 2.68B KRW | KR#1,878/2,421 Sec#181/231 |
| FCF | -1.35B KRW | KR#1,298/2,421 Sec#99/231 |
| Cash | 5.22B KRW | KR#1,985/2,421 Sec#182/231 |
| Current Ratio | 4.85x | KR#298/2,421 Sec#51/231 |
| Net Debt/EBITDA | -0.77x | KR#427/2,421 Sec#24/231 |
| Dividend | ||
| Div. Yield | 0.40% | KR#1,290/2,421 Sec#78/231 |
| Performance | ||
| 1M Return | 91.75% | KR#18/2,421 Sec#1/231 |
| From 52W High | -60.12% | KR#1,864/2,421 Sec#143/231 |
| 1Y MDD | -81.92% | KR#2,325/2,421 Sec#219/231 |
| Trading | ||
| Volume | 970,213 shares | KR#141/2,421 Sec#11/231 |
| Trading Value | 9.85B KRW | KR#255/2,421 Sec#19/231 |
| Foreign Own. | 0.77% | KR#2,122/2,421 Sec#207/231 |
| Per Share | ||
| EPS | -75 KRW | KR—/2,421 Sec—/231 |
| BPS | 6,852 KRW | KR#1,259/2,421 Sec#87/231 |
Company Info
Established in 1980 for pharmaceutical manufacturing and sales, the company founded its subsidiary, PharmBay, for specialized pharmaceutical distribution in 2020, which was listed on KOSDAQ in 2025. It specializes in cardiovascular treatments for hypertension and hyperlipidemia, as well as diabetes treatments, handling 126 professional pharmaceutical products. Cardiovascular drugs, diabetes drugs, and CMO business account for 47%, 10%, and 12% of sales, respectively, with the company enhancing competitiveness by expanding its chronic disease treatment lineup. Samik Pharm was founded in 1980 and is headquartered in Bupyeong-gu, Incheon.